TCMD Stock Analysis: Tactile Systems Technology | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 620m USD | 12M Return: 163.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 6.87M
EPS Trend: 6.6%
Qual. Beats: 0
Rev. Trend: 95.7%
Qual. Beats: 4
Warnings
No concerns identified
Tailwinds
Seasonality 9.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Tactile Systems Technology, Inc. (NASDAQ: TCMD) is a Minneapolis-based medical technology company founded in 1995 that develops and markets devices to treat underserved chronic conditions, primarily in the U.S. market. Its product portfolio centers on pneumatic compression systems-including the Flexitouch Plus, Entre Plus, and Nimbl platforms-used for lymphedema, chronic edema, venous insufficiency, and related wound care applications. The company also sells the AffloVest, a portable high-frequency chest wall oscillation device for patients with retained pulmonary secretions from conditions such as cystic fibrosis and bronchiectasis, and offers Kylee, a companion mobile app for patient self-management.
The company operates within the Health Care Equipment sub-industry, selling durable medical equipment that is typically prescribed by clinicians and reimbursed through Medicare, Medicaid, and private insurance-a model that makes coverage decisions and clinical evidence central to revenue growth. Following its 2016 IPO, TCMD has remained a small-cap player focused on the home-based chronic disease market, an area often cited as having significant unmet clinical need given the limited number of FDA-cleared, at-home treatment options for many of the conditions it targets.
- Lymphedema segment revenue growth accelerates on Flexitouch Plus demand
- Medicare reimbursement policy changes affect Flexitouch patient access and sales
- AffloVest respiratory franchise expands into bronchiectasis and CF markets
| Net Income: 20.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 0.90 > 1.0 |
| NWC/Revenue: 34.01% < 20% (prev 42.54%; Δ -8.53% < -1%) |
| CFO/TA 0.15 > 3% & CFO 42.1m > Net Income 20.3m |
| Net Debt (-59.8m) to EBITDA (41.5m): -1.44 < 3 |
| Current Ratio: 4.24 > 1.5 & < 3 |
| Outstanding Shares: last quarter (22.6m) vs 12m ago -4.85% < -2% |
| Gross Margin: 75.68% > 18% (prev 74.35%; Δ 1.33% > 0.5%) |
| Asset Turnover: 124.4% > 50% (prev 104.6%; Δ 19.77% > 0%) |
| Interest Coverage Ratio: 54.46 > 6 (EBIT TTM 35.0m / Interest Expense TTM 642k) |
| A: 0.43 (Total Current Assets 152.8m - Total Current Liabilities 36.0m) / Total Assets 272.1m |
| B: 0.20 (Retained Earnings 53.2m / Total Assets 272.1m) |
| C: 0.13 (EBIT TTM 35.0m / Avg Total Assets 276.2m) |
| D: 4.02 (Book Value of Equity 217.9m / Total Liabilities 54.2m) |
| Altman-Z'' = 8.52 = AAA |
| DSRI: 0.88 (Receivables 38.2m/36.9m, Revenue 343.5m/293.2m) |
| GMI: 0.98 (GM 74.35% / 75.68%) |
| AQI: 1.05 (AQ_t 0.37 / AQ_t-1 0.35) |
| SGI: 1.17 (Revenue 343.5m / 293.2m) |
| TATA: -0.08 (NI 20.3m - CFO 42.1m) / TA 272.1m) |
| Beneish M = -2.99 (Cap -4..+1) = A |
As of July 28, 2026, the stock is trading at USD 27.76 with a total of 123,159 shares traded. Over the past week, the price has changed by -2.22%, over one month by -8.29%, over three months by +14.52% and over the past year by +163.88%.
Current recommended Stop Loss: 26.10 (which is 6% or 1.4 ATR below the current price).
Tactile Systems Technology has received a consensus analysts rating of 3.40. Therefore, it is recommended to hold TCMD.
- StrongBuy: 1
- Buy: 0
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 39.5 | 42.3% |
P/E Trailing = 31.5862
P/E Forward = 19.1205
P/S = 1.8044
P/B = 2.843
P/EG = 17.792
Revenue TTM = 343.5m USD
EBIT TTM = 35.0m USD
EBITDA TTM = 41.5m USD
Long Term Debt = 11.9m USD (estimated: total debt 15.2m - short term 3.24m)
Short Term Debt = 3.24m USD (from shortTermDebt, last quarter)
Debt = 15.2m USD (from shortLongTermDebtTotal, last quarter) (leases 15.2m already included)
Net Debt = -59.8m USD (calculated: Debt 15.2m - CCE 75.0m)
Enterprise Value = 560.0m USD (619.8m + Debt 15.2m - CCE 75.0m)
Interest Coverage Ratio = 54.46 (Ebit TTM 35.0m / Interest Expense TTM 642k)
EV/FCF = 14.33x (Enterprise Value 560.0m / FCF TTM 39.1m)
FCF Yield = 6.98% (FCF TTM 39.1m / Enterprise Value 560.0m)
FCF Margin = 11.38% (FCF TTM 39.1m / Revenue TTM 343.5m)
Net Margin = 5.91% (Net Income TTM 20.3m / Revenue TTM 343.5m)
Gross Margin = 75.68% ((Revenue TTM 343.5m - Cost of Revenue TTM 83.6m) / Revenue TTM)
Gross Margin QoQ = 76.55% (prev 75.84%)
Tobins Q-Ratio = 2.06 (Enterprise Value 560.0m / Total Assets 272.1m)
Interest Expense / Debt = 4.23% (Interest Expense 642k / Debt 15.2m)
Taxrate = 41.19% (14.2m / 34.5m)
NOPAT = 20.6m (EBIT 35.0m * (1 - 41.19%))
Current Ratio = 4.24 (Total Current Assets 152.8m / Total Current Liabilities 36.0m)
Debt / Equity = 0.07 (Debt 15.2m / totalStockholderEquity, last quarter 217.9m)
Debt / EBITDA = -1.44 (Net Debt -59.8m / EBITDA 41.5m)
Debt / FCF = -1.53 (Net Debt -59.8m / FCF TTM 39.1m)
Total Stockholder Equity = 209.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.35% (Net Income 20.3m / Total Assets 272.1m)
RoE = 9.70% (Net Income TTM 20.3m / Total Stockholder Equity 209.2m)
RoCE = 15.81% (EBIT 35.0m / Capital Employed (Equity 209.2m + L.T.Debt 11.9m))
RoIC = 9.25% (NOPAT 20.6m / Invested Capital 222.2m)
WACC = 5.71% (E(619.8m)/V(635.0m) * Re(5.79%) + D(15.2m)/V(635.0m) * Rd(4.23%) * (1-Tc(0.41)))
Discount Rate = 5.79% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -64.91 | Cagr: -1.65%
[DCF] Terminal Value 75.91% ; FCFF base≈38.5m ; Y1≈39.9m ; Y5≈44.8m
[DCF] Fair Price = 33.35 (EV 692.4m - Net Debt -59.8m = Equity 752.2m / Shares 22.6m; r=8.35% [WACC [floored]]; 5y FCF grow 3.60% → 2.50% )
EPS Correlation: 6.61 | EPS CAGR: 2.76% | SUE: 0.59 | # QB: 0
Revenue Correlation: 95.68 | Revenue CAGR: 8.74% | SUE: 1.05 | # QB: 4
EPS current Quarter (2026-06-30): EPS=0.17 | Chg30d=+0.00% | Revisions=+25% | Analysts=2
EPS next Quarter (2026-09-30): EPS=0.39 | Chg30d=+0.00% | Revisions=+25% | Analysts=2
EPS current Year (2026-12-31): EPS=1.09 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+31.6% | GrowthRev=+10.7%
EPS next Year (2027-12-31): EPS=1.50 | Chg30d=+0.00% | Revisions=+40% | GrowthEPS=+37.4% | GrowthRev=+9.0%
[Analyst] Revisions Ratio: +44% (up=5, down=1)